JP2005500319A5 - - Google Patents

Download PDF

Info

Publication number
JP2005500319A5
JP2005500319A5 JP2003508361A JP2003508361A JP2005500319A5 JP 2005500319 A5 JP2005500319 A5 JP 2005500319A5 JP 2003508361 A JP2003508361 A JP 2003508361A JP 2003508361 A JP2003508361 A JP 2003508361A JP 2005500319 A5 JP2005500319 A5 JP 2005500319A5
Authority
JP
Japan
Prior art keywords
group
substituted
oxide
unsubstituted
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003508361A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005500319A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/020754 external-priority patent/WO2003002122A1/en
Publication of JP2005500319A publication Critical patent/JP2005500319A/ja
Publication of JP2005500319A5 publication Critical patent/JP2005500319A5/ja
Pending legal-status Critical Current

Links

JP2003508361A 2001-06-27 2002-06-27 アルツハイマー病の治療に有用なβ−ヒドロキシアミン誘導体 Pending JP2005500319A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30121001P 2001-06-27 2001-06-27
US32339601P 2001-09-18 2001-09-18
US33273601P 2001-11-19 2001-11-19
PCT/US2002/020754 WO2003002122A1 (en) 2001-06-27 2002-06-27 Beta-hydroxyamine derivatives useful in treatment of alzheimer's disease

Publications (2)

Publication Number Publication Date
JP2005500319A JP2005500319A (ja) 2005-01-06
JP2005500319A5 true JP2005500319A5 (enExample) 2006-01-05

Family

ID=27404798

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003508361A Pending JP2005500319A (ja) 2001-06-27 2002-06-27 アルツハイマー病の治療に有用なβ−ヒドロキシアミン誘導体

Country Status (7)

Country Link
US (2) US6982264B2 (enExample)
EP (1) EP1401452A1 (enExample)
JP (1) JP2005500319A (enExample)
BR (1) BR0210721A (enExample)
CA (1) CA2452039A1 (enExample)
MX (1) MXPA04000140A (enExample)
WO (1) WO2003002122A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
CA2558034A1 (en) 2004-03-09 2005-09-22 Elan Pharmaceuticals, Inc. Substituted hydroxyethylamine aspartyl protease inhibitors
WO2007047305A1 (en) 2005-10-12 2007-04-26 Elan Pharmaceuticals, Inc. Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
US7838676B2 (en) * 2005-11-21 2010-11-23 Amgen Inc. Beta-secretase modulators and methods of use
EP1971598A1 (en) 2005-11-21 2008-09-24 Amgen Inc. Beta-secretase modulators and methods of use
US7745484B2 (en) * 2005-11-21 2010-06-29 Amgen Inc. Beta-secretase modulators and methods of use
US7872009B2 (en) 2005-11-21 2011-01-18 Amgen Inc. Beta-Secretase modulators and methods of use
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
US20080277393A1 (en) * 2007-05-07 2008-11-13 True Charles W Collapsible, stackable, semi-rigid universal cotainer for hazardous and non-hazardous goods
CA2687608C (en) 2007-05-25 2013-07-02 Amgen Inc. Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
CL2008001500A1 (es) 2007-05-25 2008-12-26 Amgen Inc Compuestos derivados de hidroxietil amina sustituidas, moduladores de betasecretasa; proceso de preparacion de dichos c ompuestos; composicion farmaceutica que los comprende; y su uso para tratar un trastorno neurologico, tal como alzheimer, sindrome de down, demencia degenerativa, entre otros.
US7803809B2 (en) 2008-11-12 2010-09-28 Amgen Inc. Substituted pyrano [2,3-b] pyridinamine compounds as beta-secretase modulators and methods of use
WO2009076352A1 (en) * 2007-12-11 2009-06-18 Schering Corporation Gamma secretase modulators
EP3403650A3 (en) 2008-07-28 2019-02-13 Blanchette Rockefeller Neurosciences, Institute Pkc-activating compounds for the treatment of neurodegenerative diseases
MX2011002705A (es) * 2008-09-11 2011-09-09 Amgen Inc Compuestos con anillos espiro-triciclicos como moduladores de beta-secretasas y metodos de uso.
PL2475428T3 (pl) 2009-09-11 2015-12-31 Probiodrug Ag Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
US8822485B2 (en) 2009-11-23 2014-09-02 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
WO2011063233A1 (en) 2009-11-23 2011-05-26 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
WO2011090911A1 (en) 2010-01-19 2011-07-28 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
ES2586231T3 (es) 2010-03-03 2016-10-13 Probiodrug Ag Inhibidores de glutaminil ciclasa
MX2012010470A (es) 2010-03-10 2012-10-09 Probiodrug Ag Inhibidores heterociclicos d ciclasa de glutaminilo (qc, ec .3 2. 5).
MX2012010658A (es) 2010-03-15 2012-12-05 Amgen Inc Compuestos de anillo espiro tetraciclico como moduladores de beta-secretasa.
US8497264B2 (en) 2010-03-15 2013-07-30 Amgen Inc. Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
US9346827B2 (en) 2011-02-07 2016-05-24 Amgen Inc. 5-amino-oxazepine and 5-amino-thiazepane compounds as beta secretase antagonists and methods of use
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
WO2013044092A1 (en) 2011-09-21 2013-03-28 Amgen Inc. Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
US9725469B2 (en) 2012-11-15 2017-08-08 Amgen, Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
US20140249377A1 (en) * 2013-03-01 2014-09-04 Eugen Tarnow Well defined system and method for monitoring neurological disease onset and progress and onset of the effects of neuropharmacological drugs using the recency-primacy shift and overall free recall differences
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej

Family Cites Families (183)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3547119A (en) 1967-12-08 1970-12-15 Baxter Laboratories Inc Catheter assembly
US3739778A (en) * 1971-08-12 1973-06-19 Bard Inc C R Catheter introduction system
US3996923A (en) 1973-03-23 1976-12-14 Guerra Luis A Blood taking device
US4106491A (en) * 1975-07-24 1978-08-15 Guerra Luis A Device for prolonged intravascular infusion
JPS5753564Y2 (enExample) 1977-06-01 1982-11-19
US4126133A (en) 1977-07-13 1978-11-21 Boris Schwartz Intracorporeal catheter improvement
CH624011A5 (enExample) * 1977-08-05 1981-07-15 Battelle Memorial Institute
FR2416008A1 (fr) * 1978-02-02 1979-08-31 Oreal Lyophilisats de liposomes
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4394448A (en) * 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
DE2845643C2 (de) * 1978-10-20 1982-04-08 Max Dr. 8520 Erlangen Hubmann Katheteranschlußkopf mit mindestens einem Kanal in einem Grundkörper
US4258940A (en) * 1979-03-01 1981-03-31 Bio-Dynamics, Inc. Sealing connector for liquid and gas systems
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4311137A (en) * 1980-04-30 1982-01-19 Sherwood Medical Industries Inc. Infusion device
US5142056A (en) * 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
US4430081A (en) * 1981-01-06 1984-02-07 Cook, Inc. Hemostasis sheath
US4418944A (en) 1981-02-11 1983-12-06 Haines Stephen W Fluid coupling
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4870009A (en) * 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4668770A (en) * 1982-12-27 1987-05-26 Merck & Co., Inc. Renin inhibitory tripeptides
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US5330450A (en) * 1983-01-24 1994-07-19 Icu Medical, Inc. Medical connector
US4531937A (en) * 1983-01-24 1985-07-30 Pacesetter Systems, Inc. Introducer catheter apparatus and method of use
US5281206A (en) * 1983-01-24 1994-01-25 Icu Medical, Inc. Needle connector with rotatable collar
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4636491A (en) * 1984-03-27 1987-01-13 Merck & Co., Inc. Renin inhibitory peptides having improved solubility
US4736866B1 (en) * 1984-06-22 1988-04-12 Transgenic non-human mammals
JPH0662529B2 (ja) 1984-07-13 1994-08-17 三共株式会社 アミノ酸誘導体
US4880781A (en) 1984-08-06 1989-11-14 The Upjohn Company Renin inhibitory peptides containing an N-alkyl-histidine moiety
JPS6150912A (ja) * 1984-08-16 1986-03-13 Shionogi & Co Ltd リポソ−ム製剤の製造法
US4814270A (en) * 1984-09-13 1989-03-21 Becton Dickinson And Company Production of loaded vesicles
US4749792A (en) * 1984-09-26 1988-06-07 E. R. Squibb & Sons, Inc. Diamino ketones and alcohols as analgesic agents
US4616088A (en) 1984-10-29 1986-10-07 E. R. Squibb & Sons, Inc. Amino acid ester and amide renin inhibitor
US4665193A (en) * 1984-12-14 1987-05-12 E. R. Squibb & Sons, Inc. Amino acid ester renin inhibitors
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4753788A (en) * 1985-01-31 1988-06-28 Vestar Research Inc. Method for preparing small vesicles using microemulsification
FR2578746B1 (fr) 1985-03-12 1991-12-20 Sifc Dispositif de maintien en conditions aseptiques d'un site de connexion, d'injection ou de prelevement a usage medical
US4645495A (en) * 1985-06-26 1987-02-24 Vaillancourt Vincent L Vascular access implant needle patch
CA1290097C (en) 1985-07-24 1991-10-01 Merck & Co., Inc. Peptide enzyme inhibitors
US4729985A (en) 1985-08-09 1988-03-08 Pfizer Inc. Renin inhibitors containing 5-amino-2,5-disubstituted-4-hydroxypentanoic acid residues
US5175281A (en) 1985-09-12 1992-12-29 The Upjohn Company Pharmaceutically active pyrimidinylpiperazinylsterioids
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
WO1987002986A1 (en) 1985-11-15 1987-05-21 The Upjohn Company Novel renin inhibiting polypeptide analogs containing s-aryl-d- or l- or dl-cysteinyl, 3-(arylthio)lactic acid or 3-(arylthio)alkyl moieties
EP0258289A4 (en) 1986-01-16 1991-01-02 Joseph Dellaria Peptide analogs
US4755173A (en) * 1986-02-25 1988-07-05 Pacesetter Infusion, Ltd. Soft cannula subcutaneous injection set
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
DE3610593A1 (de) 1986-03-29 1987-10-01 Hoechst Ag Substituierte 4-amino-3-hydroxybuttersaeure-derivate verfahren zu deren herstellung, diese enthaltende mittel und ihre verwendung
EP0264106B1 (en) 1986-10-14 1994-03-16 Banyu Pharmaceutical Co., Ltd. 5-Substituted amino-4-hydroxy-pentanoic acid derivatives and their use
ES2062988T3 (es) 1986-12-19 1995-01-01 Sankyo Co Nuevos oligopeptidos inhibidores de la renina, su preparacion y su uso.
US5250565A (en) 1987-02-10 1993-10-05 Abbott Laboratories Indole-,benzofuran-,and benzothiophene-containing lipoxygenase-inhibiting compounds
DE3721855A1 (de) 1987-03-12 1988-09-22 Merck Patent Gmbh Aminosaeurederivate
FR2614533A1 (fr) 1987-04-23 1988-11-04 Sandoz Sa Nouveaux derives peptidiques, leur preparation et leur utilisation comme medicaments
WO1989000161A1 (en) 1987-06-29 1989-01-12 The Upjohn Company Malic acid derivative containing renin inhibiting peptides
US5010182A (en) * 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
EP0364493A1 (en) 1987-08-07 1990-04-25 The Upjohn Company Renin inhibiting peptides with nonpeptide linkages
GB8724885D0 (en) 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
GB8728561D0 (en) 1987-12-07 1988-01-13 Glaxo Group Ltd Chemical compounds
JPH04501201A (ja) 1987-12-21 1992-03-05 ジ・アップジョン・カンパニー 発芽植物種子類のアグロバクテリウム媒介形質転換
IL89900A0 (en) 1988-04-12 1989-12-15 Merck & Co Inc Hiv protease inhibitors useful for the treatment of aids and pharmaceutical compositions containing them
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
DE3841520A1 (de) 1988-12-09 1990-06-13 Hoechst Ag Enzymhemmende harnstoffderivate von dipeptiden, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0739904A1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US5019054A (en) * 1989-11-06 1991-05-28 Mectra Labs, Inc. Medical device valving mechanism
GB8927915D0 (en) 1989-12-11 1990-02-14 Hoffmann La Roche Novel alcohols
DE3941235A1 (de) 1989-12-14 1991-06-20 Bayer Ag Neue peptide, ihre herstellung und ihre verwendung in arzneimitteln
DE4001236A1 (de) 1990-01-18 1991-07-25 Bayer Ag Neue peptide, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel, insbesondere als arzneimittel gegen retroviren
DE4003575A1 (de) 1990-02-07 1991-08-08 Bayer Ag Retroisostere dipeptide, verfahren zur herstellung und ihre verwendung als renininhibitoren in arzneimitteln
GB9004483D0 (en) 1990-02-28 1990-04-25 Erba Carlo Spa New aryl-and heteroarylethenylene derivatives and process for their preparation
US5098394A (en) * 1990-05-31 1992-03-24 Luther Ronald B Biased shut off valve assembly for needle and catheter
US5912410A (en) * 1990-06-15 1999-06-15 Scios Inc. Transgenic non-human mice displaying the amyloid-forming pathology of alzheimer's disease
JPH06507782A (ja) * 1990-06-15 1994-09-08 サイオス　ノバ　インコーポレイテッド アルツハイマー病のアミロイド形成開症状を示すヒト以外の組換え哺乳動物
WO1992000750A1 (en) 1990-07-06 1992-01-23 Smithkline Beecham Corporation Retroviral protease inhibitors
US5176662A (en) * 1990-08-23 1993-01-05 Minimed Technologies, Ltd. Subcutaneous injection set with improved cannula mounting arrangement
US5482947A (en) * 1990-11-19 1996-01-09 Talley; John J. Retroviral protease inhibitors
US5510487A (en) * 1990-11-19 1996-04-23 G.D. Searle & Co. Retroviral protease inhibitors
US5648511A (en) * 1990-11-19 1997-07-15 G.D. Searle & Co. Method for making intermediates useful in the synthesis of retroviral protease inhibitors
AU652997B2 (en) * 1991-01-21 1994-09-15 Elan Pharmaceuticals, Inc. Test and model for alzheimer's disease
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
EP0578745A1 (en) 1991-04-04 1994-01-19 The Upjohn Company Phosphorus containing compounds as inhibitors of retroviruses
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
US5753652A (en) * 1991-07-03 1998-05-19 Novartis Corporation Antiretroviral hydrazine derivatives
IE922316A1 (en) 1991-07-17 1993-01-27 Smithkline Beecham Corp Retroviral protease inhibitors
US5516784A (en) * 1991-08-13 1996-05-14 Schering Corporation Anti-HIV (AIDS) agents
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69233109T2 (de) * 1992-01-07 2004-05-19 Elan Pharmaceuticals, Inc., San Francisco Transgene tiermodelle fur alzheimer-krankheit
EP0628035A4 (en) 1992-02-26 1995-03-29 Smithkline Beecham Corp RETROVIRAL PROTEASE INHIBITORS.
ATE116640T1 (de) * 1992-03-13 1995-01-15 Bio Mega Boehringer Ingelheim Substituierte pipecoline-säurederivate als hiv- protease-hemmer.
US5502187A (en) * 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
US5604102A (en) * 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
US5441870A (en) * 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
US5376542A (en) 1992-04-27 1994-12-27 Georgetown University Method for producing immortalized cell lines using human papilluma virus genes
US5766846A (en) * 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
DE122007000045I2 (de) * 1992-08-25 2011-07-21 Gd Searle Llc Gd Searle Llc Darunavir oder pharmazeutisch vertragliche Salze, Hydroxyethylaminosulfonamide verwendbar als InhibiEster oder Prodrugs davon. toren retroviraler Proteasen.
ATE161828T1 (de) * 1992-08-25 1998-01-15 Searle & Co Sulfonylalkanoylaminohydroxyethylaminosulfonami e verwendbar als retrovirale protease-inhibitoren
US5760076A (en) * 1992-08-25 1998-06-02 G.D Searle & Co. Succinoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US5830897A (en) 1992-08-27 1998-11-03 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US5578606A (en) * 1992-10-30 1996-11-26 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors
MX9308025A (es) 1992-12-22 1994-08-31 Lilly Co Eli Compuestos inhibidores de la proteasa del virus dela inmunodeficiencia humana, procedimiento para supreparacion y formulacion farmaceutica que los contiene.
US5484926A (en) 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
DE69329544T2 (de) * 1992-12-22 2001-05-31 Eli Lilly And Co., Indianapolis HIV Protease hemmende Verbindungen
US5545143A (en) * 1993-01-21 1996-08-13 T. S. I. Medical Device for subcutaneous medication delivery
US5461067A (en) 1993-02-25 1995-10-24 Abbott Laboratories Retroviral protease inhibiting compounds
US5257980A (en) 1993-04-05 1993-11-02 Minimed Technologies, Ltd. Subcutaneous injection set with crimp-free soft cannula
US5300045A (en) * 1993-04-14 1994-04-05 Plassche Jr Walter M Interventional needle having an automatically capping stylet
CZ184194A3 (en) 1993-08-09 1995-03-15 Lilly Co Eli Aspartylprotease inhibitor and method of identifying thereof
ES2127938T3 (es) 1993-08-24 1999-05-01 Searle & Co Hidroxietilamino sulfonamidas utiles como inhibidores de proteasas retroviricas.
US5427145A (en) * 1993-10-07 1995-06-27 Abbott Laboratories Connector with integral valve
CA2132277C (en) 1993-10-22 2005-05-10 Giorgio Cirelli Injection device
AU702293B2 (en) 1993-10-27 1999-02-18 Athena Neurosciences, Inc. Transgenic animals harboring APP allele having Swedish mutation
JPH07126286A (ja) 1993-11-05 1995-05-16 Yamanouchi Pharmaceut Co Ltd 新規なペプチド誘導体
US5733882A (en) * 1994-01-17 1998-03-31 Smithkline Beecham Corporation Retroviral protease inhibitors
US5877399A (en) * 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
US5625031A (en) * 1994-02-08 1997-04-29 Bristol-Myers Squibb Company Peptide inhibitors of the p33cdk2 and p34cdc2 cell cycle regulatory kinases and human papillomavirus E7 oncoprotein
US5475138A (en) 1994-07-07 1995-12-12 Pharm-Eco Laboratories Incorporated Method preparing amino acid-derived diaminopropanols
DE69527405T2 (de) * 1994-10-19 2003-03-13 Novartis Ag, Basel Antivirale Ether von Aspartat-Protease-Substrat-Isosteren
US6001813A (en) 1994-11-21 1999-12-14 Cortech Inc. Val-pro containing α-keto oxadiazoles as serine protease inhibitors
DE4442352C1 (de) * 1994-11-29 1995-12-21 Braun Melsungen Ag Ventilvorrichtung
US5481011A (en) * 1994-12-13 1996-01-02 Bristol-Myers Squibb Company Process for preparing N-protected amino acid α-halomethyl ketones and alcohols from N-protected amino acid esters
US5863902A (en) * 1995-01-06 1999-01-26 Sibia Neurosciences, Inc. Methods of treating neurodegenerative disorders using protease inhibitors
US5804560A (en) 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US5831117A (en) 1995-01-20 1998-11-03 G. D. Searle & Co. Method of preparing retroviral protease inhibitor intermediates
DE69637380T2 (de) 1995-01-20 2009-09-17 G.D. Searle Llc, Chicago Bis-sulfonamid-hydroxyethylamino-derivate als inhibitoren retroviraler proteasen
MY113488A (en) * 1995-01-27 2002-03-30 Novo Nordisk As Compounds with growth hormone releasing properties
US5545640A (en) * 1995-04-04 1996-08-13 Bio-Mega/Boehringer Ingeleheim Research Inc. Protease inhibiting succinic acid derivatives
US5565483A (en) * 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators
US5744346A (en) * 1995-06-07 1998-04-28 Athena Neurosciences, Inc. β-secretase
JPH11507538A (ja) * 1995-06-07 1999-07-06 アテナ ニューロサイエンシズ インコーポレイティド β−セクレターゼ、β−セクレターゼに対する抗体、及びβ−セクレターゼ阻害を検出するためのアッセイ
IE77523B1 (en) * 1995-09-11 1997-12-17 Elan Med Tech Medicament delivery device
US5858001A (en) * 1995-12-11 1999-01-12 Elan Medical Technologies Limited Cartridge-based drug delivery device
US5849691A (en) 1996-02-20 1998-12-15 The United States Of America As Represented By The Department Of Health And Human Services Peptidomimetic inhibitors of cathepsin D and plasmepsins I and II
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
CA2251066A1 (en) 1996-05-07 1997-11-13 Boehringer Ingelheim Pharmaceuticals, Inc. Process for preparing oxiranemethanamine derivatives
EP1184370B1 (en) * 1996-07-22 2005-09-14 Novo Nordisk A/S Compounds with growth hormone releasing properties
US5703129A (en) * 1996-09-30 1997-12-30 Bristol-Myers Squibb Company 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of β-amyloid protein production
DE69738653T2 (de) 1996-11-20 2009-06-04 Oklahoma Medical Research Foundation, Oklahoma Klonierung und charakterisierung von napsin, einer aspartat-protease
US6153652A (en) 1996-11-22 2000-11-28 Elan Pharmaceuticals, Inc. N-(aryl/heteroaryl/alkylacetyl) amino acid amides, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6191166B1 (en) * 1997-11-21 2001-02-20 Elan Pharmaceuticals, Inc. Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis
US6127556A (en) 1996-12-31 2000-10-03 G. D. Searle & Co. Epoxide formation by continuous in-situ synthesis process
WO1998033795A1 (en) 1997-02-04 1998-08-06 The Regents Of The University Of California Nanomolar, non-peptide inhibitors of cathepsin d
US5851197A (en) 1997-02-05 1998-12-22 Minimed Inc. Injector for a subcutaneous infusion set
US6093172A (en) * 1997-02-05 2000-07-25 Minimed Inc. Injector for a subcutaneous insertion set
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
SK112899A3 (en) 1997-02-26 2001-05-10 Pfizer Heteroaryl-hexanoic acid amide derivatives, their preparation and their use as selective inhibitors of mip-1-alpha binding to its ccr1 receptor
US6221670B1 (en) * 1997-03-21 2001-04-24 Scios Inc. Methods to identify β-amyloid reducing agents
US6186982B1 (en) * 1998-05-05 2001-02-13 Elan Corporation, Plc Subcutaneous drug delivery device with improved filling system
EP0983228A4 (en) 1997-05-08 2002-08-07 Smithkline Beecham Corp PROTEASE INHIBITORS
US5968011A (en) 1997-06-20 1999-10-19 Maersk Medical A/S Subcutaneous injection set
US5962506A (en) 1997-07-07 1999-10-05 Pharmacopeia, Inc. Glycol and hydroxyphosphonate peptidomimetics as inhibitors of aspartyl proteases
US6213973B1 (en) * 1998-01-12 2001-04-10 C. R. Bard, Inc. Vascular access port with elongated septum
EP1053243B1 (en) 1998-02-12 2011-03-30 Emory University Sphingolipid derivatives and their methods of use
US6095997A (en) * 1998-03-04 2000-08-01 Corvascular, Inc. Intraluminal shunt and methods of use
US6056718A (en) * 1998-03-04 2000-05-02 Minimed Inc. Medication infusion set
US5980506A (en) 1998-03-20 1999-11-09 Mathiasen; Orla Subcutaneous infusion device
DE19817461A1 (de) 1998-04-20 1999-10-21 Basf Ag Neue substituierte Benzamide, deren Herstellung und Anwendung
USD404482S (en) 1998-05-01 1999-01-19 Elan Medical Technologies Limited Drug delivery device
DE19821723C2 (de) 1998-05-14 2000-07-06 Disetronic Licensing Ag Katheterkopf für subkutane Verabreichung eines Wirkstoffs
BR9912169A (pt) 1998-06-19 2001-04-10 Vertex Pharma Inibidores de sulfonamida de protease de aspartil
US6355021B1 (en) * 1998-07-14 2002-03-12 Maersk Medical A/S Medical puncturing device
ES2318902T3 (es) 1998-09-24 2009-05-01 PHARMACIA & UPJOHN COMPANY LLC Secretasa en la enfermedad del alzheimer.
WO2000047618A2 (en) 1999-02-10 2000-08-17 Elan Pharmaceuticals, Inc. HUMAN β-SECRETASE ENZYME, INHIBITORS AND THEIR COMPOSITIONS AND USES
CA2367112A1 (en) 1999-03-24 2000-09-28 The Regents Of The University Of California Methods for treating neurodegenerative disorders using aspartyl protease inhibitors
EP1171591A1 (en) 1999-04-09 2002-01-16 Human Genome Sciences, Inc. 48 human secreted proteins
US6419699B1 (en) * 1999-04-14 2002-07-16 Mcghan Medical Corporation Universal implant fill connector
US7087399B1 (en) 1999-05-13 2006-08-08 Scios, Inc. β-secretase and modulation of β-secretase activity
JP2003502342A (ja) 1999-06-15 2003-01-21 エラン ファーマスーティカルズ インコーポレイテッド ベータ−セクレターゼのスタチン誘導テトラペプチド阻害剤
EP1194449B1 (en) 1999-06-28 2010-09-22 Oklahoma Medical Research Foundation Inhibitors of memapsin 2 and use thereof
AU7757400A (en) 1999-08-09 2001-03-05 Vanderbilt University Antiviral therapy use of p-glycoprotein modulators
AU783914B2 (en) 1999-09-13 2005-12-22 Bristol-Myers Squibb Pharma Company Hydroxyalkanoyl aminolactams and related structures as inhibitors of a beta protein production
DK1224297T3 (da) 1999-09-23 2009-09-07 Pharmacia & Upjohn Co Llc Alzheimers sygdom -sekretase, APP-substrater derfor og anvendelser deraf
GB9924957D0 (en) 1999-10-21 1999-12-22 Smithkline Beecham Plc Novel treatment
WO2001051659A2 (en) 2000-01-13 2001-07-19 Genset Biallelic markers derived from genomic regions carrying genes involved in central nervous system disorders
AU2001252958A1 (en) 2000-03-23 2001-10-03 Elan Pharmaceuticals, Inc. Compounds and methods to treat alzheimer's disease
US6846813B2 (en) 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
CA2410680A1 (en) 2000-06-30 2002-01-10 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
US20030096864A1 (en) 2000-06-30 2003-05-22 Fang Lawrence Y. Compounds to treat alzheimer's disease
IL157561A0 (en) 2001-03-04 2004-03-28 Sterling Medivations Inc Infusion hub assembly and fluid line disconnect system
AR039555A1 (es) 2001-11-08 2005-02-23 Upjohn Co Derivados n,n'-sustituidos de 1,3-diamino-2-hidroxipropano

Similar Documents

Publication Publication Date Title
AR039555A1 (es) Derivados n,n'-sustituidos de 1,3-diamino-2-hidroxipropano
JP2004502664A5 (enExample)
AR031852A1 (es) Compuestos para tratar enfermedad de alzheimer
ES2552549T3 (es) Compuestos de carboxamida para el tratamiento de trastornos metabólicos
EP1910336B1 (en) Monohydrochloride monohydrate salt of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
WO2006032999A1 (en) N-methyl hydroxyethylamine useful in treating cns conditions
YU21695A (sh) Novi derivati eritromicina, potupak za njihovo dobivanje i njihova primena kao lekova
WO2005060665A3 (en) 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors
JP2012517965A5 (enExample)
ATE520695T1 (de) Substituierte rylenderivate
CA2620361C (en) Poly-beta-peptides from functionalized beta-lactam monomers and antibacterial compositions containing same
JP2007537275A5 (enExample)
CA2452039A1 (en) Beta-hydroxyamine derivatives useful in treatment of alzheimer's disease
EP1961734A4 (en) AMINE CONNECTION AND ITS USE FOR MEDICAL PURPOSES
CN119823023A (zh) 制备官能化环辛烯的工艺
CN114391013A (zh) 一种irak抑制剂及其制备方法和用途
JP2004534771A5 (enExample)
JP2004535424A5 (enExample)
AR042746A1 (es) Derivados de arilalquilcarbamatos, su preparacion y su aplicacion en terapeutica.
GB0413630D0 (en) Process
JP2021528421A5 (enExample)
CA2528590A1 (en) 4-(aminomethyl)-piperidine benzamides as 5ht4-antagonists
ATE490986T1 (de) Polymer, vernetztes polymer, zusammensetzung für ein feststoffpolymer-elektrolyt, feststoffpolymer-elektrolyt und klebstoffzusammensetzung
WO2007135080A3 (en) (2r)-2-[(4-sulfonyl)aminophenyl]propanamides and pharmaceutical compositions containing them
JP2005536448A5 (enExample)